Ameren vs Unitil
AEE and UTL side by side, both in combination electric and gas, and other utility. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AEE and UTL compare
Ameren is the larger company, worth 31 times as much as Unitil ($31.4B against $1.0B).
On earnings, Unitil is cheaper: it trades at 18.1× trailing earnings, against 20.0× for Ameren.
Unitil grew revenue faster over the last twelve months (21.1% versus 3.8% for Ameren).
Both pay dividends: Ameren yields 2.6% and Unitil 3.4%.
Unitil scores higher on the StockData Score (10 against 3 for Ameren), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AEE | UTL |
|---|---|---|
| Size and price | ||
| Market cap | $31.4B | $1.0B |
| Share price | $113.52 | $55.66 |
| Change, 1 year | 7.9% | 15.0% |
| Change, 5 years | 33.0% | 34.9% |
| Beta (5Y) | 0.36 | 0.25 |
| Employees | – | 595 |
| StockData Score | ||
| Total score | 3 | 10 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 0 | 0 |
| Dividend score | 2 | 3 (better) |
| Valuation | ||
| P/E | 20.0× | 18.1× (better) |
| P/S | 3.6× | 1.7× (better) |
| P/B | 2.3× | 1.6× (better) |
| EV/EBITDA | 13.9× (better) | 17.7× |
| PEG | 2.24 (better) | 3.87 |
| FCF yield | −4.5% | −3.9% (better) |
| Fair value | $104.30 | $52.22 |
| Margin of safety | −8.8% | −6.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 3.8% | 21.1% (better) |
| Revenue growth, 5Y average | 8.7% (better) | 5.1% |
| Net income growth (TTM) | – | 18.4% |
| EPS growth (TTM) | 24.8% (better) | 6.6% |
| EPS growth, 5Y average | 8.9% (better) | 6.7% |
| Profitability | ||
| Operating margin | 24.9% (better) | 18.6% |
| Net margin | – | 9.1% |
| FCF margin | −16.0% | −6.6% (better) |
| Return on equity | – | 9.0% |
| Return on invested capital | 5.9% (better) | 5.7% |
| Financial health | ||
| Debt / equity | 1.59 | 1.54 (better) |
| Net debt / EBITDA | 5.68 (better) | 8.66 |
| Interest coverage | 2.6× | – |
| Current ratio | 0.53 (better) | 0.50 |
| Altman Z-score | 0.91 (better) | 0.82 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Dividend yield | 2.6% | 3.4% (better) |
| Payout ratio | – | 61.0% |
| Years of dividend growth | 12 (better) | 11 |
| Dividend growth, 5Y average | 7.3% (better) | 3.7% |
| Buyback yield | −1.8% | −1.7% (better) |
| Shareholder yield | 0.79% | 1.6% (better) |
| Ownership | ||
| Held by institutions | 88.5% | 84.2% |
| Held by insiders | 0.36% | 0.71% |
| Insider net buying, 12 months | −$8.1M | – |
| Short interest, % of float | 5.7% | 3.6% |
Go deeper
- AEE stock overview
- AEE income statement
- AEE valuation and score
- UTL stock overview
- UTL income statement
- UTL valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.